-+ 0.00%
-+ 0.00%
-+ 0.00%

MAIA BIOTECHNOLOGY ANNOUNCES FIRST PATIENT DOSED IN THIO-104 PHASE 3 PIVOTAL TRIAL EVALUATING ATEGANOSINE AS THIRD-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER

Reuters·12/11/2025 14:00:02

Please log in to view news